Charles River Laboratories International (CRL) Research Hub

Charles River Laboratories International (CRL) trades on NYSE, US in the Healthcare (Medical - Diagnostics & Research) sector. As of 2026-09-11, shares last closed at 278.26 USD (-0.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -58.32, market cap 10.63B. This hub links to the full technical, earnings and options research available for CRL.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Medical - Diagnostics & Research)
ExchangeNYSE, US
Last close278.26 USD (-0.03%)
52-week range178.92 USD – 300.59 USD
Trend regimeRange
14-day RSI57.4 (Bullish)
Trailing P/E-58.32
Market cap10.63B
Dividend yield0.00%

Available research for CRL

Earnings

CRL earnings: real EPS beat/miss history, analyst consensus Buy, P/E -58.32. Updated 2026-07-23.

Options: Covered Call

Covered Call on CRL: how it works, illustrative setup around the real 278.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on CRL: how it works, illustrative setup around the real 278.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on CRL: how it works, illustrative setup around the real 278.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

CRL technical analysis: range, last 278.26 USD, RSI 57.4, 52w range 178.92 USD–300.59 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is CRL in?

Charles River Laboratories International (CRL) is classified under Healthcare (Medical - Diagnostics & Research), listed on NYSE, US.

Is CRL in an uptrend or downtrend?

As of 2026-09-11, CRL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is CRL's trailing P/E ratio?

CRL's trailing P/E is -58.32, with a market cap of 10.63B. See the earnings research page for full valuation detail.